Endocrinology

 
Sotagliflozin: CV Benefit Seen in Patients with T2 Diabetes, Worsening Heart Failure
January 14, 2021

Sotagliflozin reduced CV death and hospitalization for HF in patients with T2D and acute symptomatic HF when given during or immediately after hospitalization.

SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients
December 08, 2020

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

DAPA-CKD Investigator: "PCPs Should be First-line Prescribers of SGLT2 Inhibitors"
December 03, 2020

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.